➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Baxter
McKinsey
Moodys
Dow

Last Updated: June 15, 2021

DrugPatentWatch Database Preview

CAPOTEN Drug Profile


Email this page to a colleague

« Back to Dashboard

When do Capoten patents expire, and when can generic versions of Capoten launch?

Capoten is a drug marketed by Par Pharm and is included in one NDA.

The generic ingredient in CAPOTEN is captopril. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the captopril profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Capoten

A generic version of CAPOTEN was approved as captopril by HIKMA INTL PHARMS on February 13th, 1996.

  Get Started Free

Drug patent expirations by year for CAPOTEN
Recent Clinical Trials for CAPOTEN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of NebraskaPhase 4

See all CAPOTEN clinical trials

Paragraph IV (Patent) Challenges for CAPOTEN
Tradename Dosage Ingredient NDA Submissiondate
CAPOTEN TABLET;ORAL captopril 018343

US Patents and Regulatory Information for CAPOTEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm CAPOTEN captopril TABLET;ORAL 018343-005 Jan 17, 1985 DISCN Yes No   Get Started Free   Get Started Free   Get Started Free
Par Pharm CAPOTEN captopril TABLET;ORAL 018343-004 Jun 13, 1995 DISCN Yes No   Get Started Free   Get Started Free   Get Started Free
Par Pharm CAPOTEN captopril TABLET;ORAL 018343-001 Approved Prior to Jan 1, 1982 DISCN Yes No   Get Started Free   Get Started Free   Get Started Free
Par Pharm CAPOTEN captopril TABLET;ORAL 018343-002 Approved Prior to Jan 1, 1982 DISCN Yes No   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CAPOTEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Pharm CAPOTEN captopril TABLET;ORAL 018343-004 Jun 13, 1995   Get Started Free   Get Started Free
Par Pharm CAPOTEN captopril TABLET;ORAL 018343-003 Approved Prior to Jan 1, 1982   Get Started Free   Get Started Free
Par Pharm CAPOTEN captopril TABLET;ORAL 018343-005 Jan 17, 1985   Get Started Free   Get Started Free
Par Pharm CAPOTEN captopril TABLET;ORAL 018343-001 Approved Prior to Jan 1, 1982   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Express Scripts
Boehringer Ingelheim
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.